Tags

Type your tag names separated by a space and hit enter

Peptide histidine isoleucine-like immunoreactivity release from the rat gastric fundus.
Br J Pharmacol. 1994 Oct; 113(2):541-9.BJ

Abstract

1. Longitudinal muscle strips from the rat gastric fundus were subjected to in vitro electrical field stimulation (EFS) under non-adrenergic non-cholinergic (NANC) conditions to study the release of peptide histidine isoleucine-like immunoreactivity (PHI-LI) and the correlation between PHI-LI release and NANC relaxation. 2. Different radioimmunoassay (RIA) systems employing C-terminal- and N-terminal-specific anti-PHI sera were used to determine the relative contributions of PHI and its C-terminally extended forms, peptide histidine glycine (PHI-Gly) and peptide histidine valine [PHV(1-42)], to the PHI-LI released by the rat gastric fundus. 3. In the presence of atropine (1 microM) and guanethidine (5 microM), EFS (120 mA, 1 ms, 0.25-32.0 Hz, trains of 2 min) induced frequency-dependent relaxations of 5-hydroxytryptamine (3 microM) pre-contracted strips. 4. EFS at frequencies of 8-32 Hz evoked significant increases in PHI-LI outflow. The increases in PHI-LI outflow evoked by 16-Hz EFS were abolished by tetrodotoxin (3 microM) and by a calcium-free medium, indicating an active release process from intramural nerves. 5. The EFS-induced release of PHI-LI measured with the N-terminal-specific antiserum was significantly greater than that detected with the C-terminal-specific antisera. 6. Sephadex G-25 gel permeation chromatographic analysis was performed on the PHI-LI release in response to 32-Hz EFS. A C-terminal-specific antiserum revealed one peak co-eluting with the rat PHI standard. When PHI-LI was measured with the N-terminal-specific antiserum, two peaks were found that co-eluted with the rat PHV(1-42) and rat PHI-Gly/PHI standards, respectively. 7. The present data suggest that the extended forms of PHI are the primary components of the PHI-LI released by NANC inhibitory neurones in the rat gastric fundus and support a NANC inhibitory neurotransmitter role for PHI and its extended forms in this tissue.

Authors+Show Affiliations

Institute of Pharmacology, Catholic University School of Medicine, Rome, Italy.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

7834206

Citation

Currò, D, et al. "Peptide Histidine Isoleucine-like Immunoreactivity Release From the Rat Gastric Fundus." British Journal of Pharmacology, vol. 113, no. 2, 1994, pp. 541-9.
Currò D, Preziosi P, Ragazzoni E, et al. Peptide histidine isoleucine-like immunoreactivity release from the rat gastric fundus. Br J Pharmacol. 1994;113(2):541-9.
Currò, D., Preziosi, P., Ragazzoni, E., & Ciabattoni, G. (1994). Peptide histidine isoleucine-like immunoreactivity release from the rat gastric fundus. British Journal of Pharmacology, 113(2), 541-9.
Currò D, et al. Peptide Histidine Isoleucine-like Immunoreactivity Release From the Rat Gastric Fundus. Br J Pharmacol. 1994;113(2):541-9. PubMed PMID: 7834206.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Peptide histidine isoleucine-like immunoreactivity release from the rat gastric fundus. AU - Currò,D, AU - Preziosi,P, AU - Ragazzoni,E, AU - Ciabattoni,G, PY - 1994/10/1/pubmed PY - 1994/10/1/medline PY - 1994/10/1/entrez SP - 541 EP - 9 JF - British journal of pharmacology JO - Br. J. Pharmacol. VL - 113 IS - 2 N2 - 1. Longitudinal muscle strips from the rat gastric fundus were subjected to in vitro electrical field stimulation (EFS) under non-adrenergic non-cholinergic (NANC) conditions to study the release of peptide histidine isoleucine-like immunoreactivity (PHI-LI) and the correlation between PHI-LI release and NANC relaxation. 2. Different radioimmunoassay (RIA) systems employing C-terminal- and N-terminal-specific anti-PHI sera were used to determine the relative contributions of PHI and its C-terminally extended forms, peptide histidine glycine (PHI-Gly) and peptide histidine valine [PHV(1-42)], to the PHI-LI released by the rat gastric fundus. 3. In the presence of atropine (1 microM) and guanethidine (5 microM), EFS (120 mA, 1 ms, 0.25-32.0 Hz, trains of 2 min) induced frequency-dependent relaxations of 5-hydroxytryptamine (3 microM) pre-contracted strips. 4. EFS at frequencies of 8-32 Hz evoked significant increases in PHI-LI outflow. The increases in PHI-LI outflow evoked by 16-Hz EFS were abolished by tetrodotoxin (3 microM) and by a calcium-free medium, indicating an active release process from intramural nerves. 5. The EFS-induced release of PHI-LI measured with the N-terminal-specific antiserum was significantly greater than that detected with the C-terminal-specific antisera. 6. Sephadex G-25 gel permeation chromatographic analysis was performed on the PHI-LI release in response to 32-Hz EFS. A C-terminal-specific antiserum revealed one peak co-eluting with the rat PHI standard. When PHI-LI was measured with the N-terminal-specific antiserum, two peaks were found that co-eluted with the rat PHV(1-42) and rat PHI-Gly/PHI standards, respectively. 7. The present data suggest that the extended forms of PHI are the primary components of the PHI-LI released by NANC inhibitory neurones in the rat gastric fundus and support a NANC inhibitory neurotransmitter role for PHI and its extended forms in this tissue. SN - 0007-1188 UR - https://www.unboundmedicine.com/medline/citation/7834206/Peptide_histidine_isoleucine_like_immunoreactivity_release_from_the_rat_gastric_fundus_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0007-1188&date=1994&volume=113&issue=2&spage=541 DB - PRIME DP - Unbound Medicine ER -